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Objective: To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe
ﬁbrosis/cirrhosis in HCV seroconverters among persons with human immunodeﬁciency virus (HIV)
infection.
Methods: We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy.
Results: Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-
who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe ﬁbrosis/
cirrhosis was 30% by 10 years after seroconversion.
Conclusions: New HCV infections have a rapidly progressive course in this population. Persons with HIV
and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.
M. Puoti, Clin Microbiol Infect 2017;23:267
© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Liver disease due to hepatitis C virus (HCV) infection is a major
cause of morbidity andmortality among persons living with human
immunodeﬁciency virus (HIV) [1,2], and there is evidence that HIV
infection may increase the rate of progression to liver cirrhosis [3].
Studies conducted on small series of patients in the context of an
increased spread of HCV infection among HIV-infected men-who-ference on Retroviruses and
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ology Unit, National Institute
92, 00194 Roma, Italy.
da Hospital, Milano, Italy
biology and Infectious Diseases. Puhave-sex-with-men (MSM) [4e6], suggested that newly acquired
HCV infection may lead to rapid progression of ﬁbrosis.
The aim of our analysis was to estimate the incidence and pre-
dictors of HCV seroconversion and the risk of progression to
cirrhosis in HCV seroconverters among persons living with HIV in
Italy.Materials and methods
We studied persons living with HIV enrolled in an observational
multicentre cohort study in Italy, the ICONA Foundation Study [7].
Patients included in this analysis were those with an negative anti-
HCV test, in whom at least a second anti-HCV test was performed.
Individual follow up accrued from the time of the ﬁrst HCV-
negative test and ended at the time of their ﬁrst positive or last
negative test. We deﬁned the time of occurrence of seroconversionblished by Elsevier Ltd. All rights reserved.
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the ﬁrst positive tests. We estimated HCV incidence as number of
HCV seroconversions observed divided by person-years of follow
up (PYFU). The determinants of seroconversion were analysed by
Cox regression model, which included gender, mode of HIV trans-
mission, age, clinical stage, hepatitis B surface antigen (HBsAg)
status, Treponema pallidum serum antibodies and previous sexually
transmitted disease at baseline, and the following time-updated
covariates: CD4 cell count, plasma HIV RNA, antiretroviral treat-
ment and alcohol use. Among HCV seroconverters, we analysed the
progression to severe ﬁbrosis/cirrhosis deﬁned as the occurrence of
liver-related death, liver decompensation, a clinical diagnosis of
cirrhosis or a FIB-4 score >3.25 [8]. We estimated the risk of pro-
gression using KaplaneMeier method and analysed predictors of
progression with a Cox regression model including: gender, mode
of HIV transmission, age, clinical stage, CD4 cell count, HIV viral
load, HBsAg status at seroconversion and time-updated alcohol use.Results
Of the 4059 patients included in the analysis, 1787 (44.0%) were
tested twice, 870 (21.4%) were tested three times, and 1402 (34.6%)
were tested four or more times. Over a total of 28 867 PYFU, 185
seroconversions were recorded; the estimated Incidence Rate of
HCV infection was 0.6 per 100 PYFU (95% CI 0.5e0.7).
Incidence rate of HCV seroconversion was highest among
injecting drug users (IDUs) (7.2 per 100 PYFU, 95% CI 5.4e9.6),
followed by MSM (0.7 per 100 PYFU, 95% CI 0.6e0.9), heterosexual
contacts (0.3 per 100 PYFU, 95% CI 0.2e0.4). Over time, incidence
rates decreased in the overall study population (from 1.6 per 100
PYFU in 1997e2000, to 0.4 in 2013e2016) and among IDUs (from
17.1 per 100 PYFU, in 1997e2000 to 1.0 in 2013e2016) (Fig. 1). In
contrast, the incidence ratewas stable in MSM (0.8 per 100 PYFU, in
1997e2000 and 0.8 in 2013e2016).
In multivariable analysis, being an IDU (relative hazard (RH)
19.04, 95% CI 11.63e31.18) or MSM (RH 1.97, 95% CI 1.22e3.19)
compared with heterosexuals, and being positive for Treponema
(RH 2.02, 95% CI 1.28e3.18) were associated with a higher risk of
seroconversion. Lower risk was associated with older age (RH 0.79
per 10 years older, 95% CI 0.65e0.96) (see Supplementary material,
Table S1).
Thirty-one patients started a treatment for HCV infection, of
whom 27 received interferon-based treatments and four receivedFigure 1. Incidence rates of hepatitis C virus seroconversion by cdirect-acting antiviral-based treatments. Among the 185 sero-
converters, 35 developed severe ﬁbrosis/cirrhosis (34 FIB-4 >3.25
and one clinical diagnosis of cirrhosis) over 958 PYFU for an esti-
mated rate of 3.6 per 100 PYFU (95% CI 2.6e5.1). Estimated cu-
mulative probability of progression to cirrhosis was 7.4% (95% CI
4.2e12.7) by 2 years, 17.1% (95% CI 11.7e24.6) by 5 years and 29.9%
(95% CI 21.5e40.5) by 10 years from seroconversion (Fig. 2). In
multivariable analysis, IDU as mode of HIV transmission (RH 3.47,
95% CI 1.47e10.48) and alcohol use (RH 20.79, 95% CI 1.57e274.80)
were associated with progression to cirrhosis (see Supplementary
material, Table S2).Discussion
The incidence of new HCV infection in our cohort was of the
same order of magnitude as that reported in other cohort studies
[9,10]. Consistently with previous reports [9,11] we observed a
decreasing trend in incidence among IDUs, whereas, although a
non-negligible incidence of HCV in MSM was recorded, we did not
observe the increasing trend in incidence in these patients that has
been reported in other cohorts [10]. Nonetheless, our data suggest a
potential usefulness of periodic HCV testing for IDUs and MSM
living with HIV.
In a meta-analysis of observational studies on persons living
with HIV with prevalent HCV infection, the predicted cumulative
probability of cirrhosis 10 years after the estimated date of HCV
infection was 2.3% [3]. In our study we estimated a progression to
cirrhosis of 30% 10 years after HCV seroconversion, and this ﬁnding
is consistent with the hypothesis that among persons living with
HIV the course of HCV infection is worse when it is acquired after
HIV, compared with that observed among HCV-infected persons
who acquire HIV after HCV or at the same time. The risk of pro-
gression to cirrhosis in our study was not associated with HIV-
related factors such as CD4 cells count and HIV viral load.
This study has some limitations: information on alcohol and
recreational drug use was incomplete, the frequency of anti-HCV
tests was lower than in other studies [12] and the deﬁnition of
liver disease progressionwasmainly based on FIB-4 score, although
a recent study suggests that this score is highly predictive of liver-
related events in HIVeHCV co-infected individuals [13]. On the
other hand, the number of seroconversions that we recorded is
larger than that reported in other cohort studies analysed so far
[10].alendar year and human immunodeﬁciency virus risk factor
Figure 2. KaplaneMeier estimate of the probability of progressing to hepatitis C virus-
related severe ﬁbrosis/cirrhosis in persons living with human immunodeﬁciency virus
with hepatitis C virus seroconversion in the Icona cohort
M. Puoti et al. / Clinical Microbiology and Infection 23 (2017) 267.e1e267.e4 267.e3The advent of direct-acting antivirals has revolutionized the
therapy of HCV infection, as these drugs may cure al least 90% of
patients, regardless of the presence of HIV co-infection [14].
Nonetheless, the high cost of these drugs has forced health systems,
even in resource-rich countries, to adopt rationing policies that
have in practice limited the access to these drugs to the sickest
patients. Our data, strongly suggest that persons with HIV and HCV
superinfection, regardless of the severity of liver disease, should be
prioritized for direct-acting antivirals treatment.
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